BAYER AG/ DE000BAY0017 /
2025-05-07 11:13:55 AM | Chg. -0.30 | Volume | Bid11:30:27 AM | Ask11:30:27 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
23.77EUR | -1.23% | 35 Turnover: 831.95 |
23.73Bid Size: 442 | 23.75Ask Size: 442 | 23.39 bill.EUR | 0.46% | - |
GlobeNewswire
05-06
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
05-06
Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and ...
GlobeNewswire
04-25
Freight Technologies Integrates with Blue Yonder TMS Through Bayer to Optimize Supply Chain Efficien...
GlobeNewswire
04-16
BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial f...
GlobeNewswire
03-07
AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosin...
GlobeNewswire
02-27
UPDATE - YourUpdateTV Speaks with Alanna Morris-Simon from Bayer to Discuss Key Risk Factors for Hea...
GlobeNewswire
02-24
YourUpdateTV Speaks with Alanna Morris-Simon from Bayer to Discuss Key Risk Factors for Heart Diseas...
GlobeNewswire
02-19
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease inves...
GlobeNewswire
02-13
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Fail...
GlobeNewswire
2024-08-02
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
2024-07-11
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
2024-05-30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
2024-05-30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
2024-05-28
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement